2022
Prognostic value of age-sex adjusted NT-proBNP ratio in obstructive hypertrophic cardiomyopathy
Hutt E, Mentias A, Alashi A, Wadhwa R, Fava A, Lever HM, Thamilarasan M, Popovic ZB, Smedira NG, Desai MY. Prognostic value of age-sex adjusted NT-proBNP ratio in obstructive hypertrophic cardiomyopathy. Progress In Cardiovascular Diseases 2022, 74: 11-18. PMID: 35952727, DOI: 10.1016/j.pcad.2022.08.002.Peer-Reviewed Original ResearchConceptsSeptal reduction therapyBNP ratioNT-proBNP ratioPrimary outcomeAsymptomatic patientsPrognostic valueObstructive hypertrophic cardiomyopathy patientsIncremental prognostic valueNormal NT-proBNPNT-pro BNPObstructive hypertrophic cardiomyopathyLong-term outcomesHypertrophic cardiomyopathy patientsCardiac transplantationNT-proBNPPrimary endpointCardiomyopathy patientsHypertrophic cardiomyopathyReduction therapyHigh riskPatientsDefibrillator dischargeSpline analysisOutcomesBNP
2021
Predictive value of NT-proBNP in non-obstructive hypertrophic cardiomyopathy
Hutt E, Mentias A, Alashi A, Fava A, Popovic Z, Thamilarasan M, Lever H, Desai M. Predictive value of NT-proBNP in non-obstructive hypertrophic cardiomyopathy. European Heart Journal 2021, 42: ehab724.0765. DOI: 10.1093/eurheartj/ehab724.0765.Peer-Reviewed Original ResearchNT-proBNP ratioLV ejection fractionSerum NT-proBNPNT-proBNPAsymptomatic patientsPrimary endpointSeptal myectomySudden cardiac death risk factorsNon-obstructive hypertrophic cardiomyopathyKaplan-Meier survival analysisDeath risk factorsEarly disease stagesHypertrophic cardiomyopathy patientsImplantable defibrillator dischargesEjection fractionHeart transplantPrimary outcomeRisk stratificationPrognostic valueAdverse outcomesDisease stageCardiomyopathy patientsRisk factorsEcho variablesHypertrophic cardiomyopathy